Does systemic anti-tumor therapy increase COVID-19 risk in patients with cancer?

ABSTRACT:

Purpose

We aimed to determine the COVID-19 infection rate and determine the factors that affect hospitalization and prognosis in patients receiving systemic chemotherapy (CT), immunotherapy (IT) and molecular-targeted therapies at our hospital within three months after the onset of COVID-19 pandemic.

Materials and methods

The patients who received systemic treatment at chemotherapy unit with diagnosis of cancer between 11 March 2020 and 11 June 2020 were included. The clinical and demographic characteristics of patients, the systemic treatments that they received (CT, IT, targeted therapies), and the stage of disease were determined. For the parameters that affect the hospitalization of COVID-19 infected patients were also determined.

Results

Among 1149 patients with

SUBMITTER: Ayhan M 

PROVIDER: S-EPMC8107490 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature